Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Deborah Collyar: What's In It for Patients?

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Feb

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Deborah Collyar: What's In It for Patients?

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

‘Prostate Screening Saved My Life’—Is That Really True In Most Cases?

SABCS 2025: Top Picks From a Breast Cancer Specialist

Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer

How the Outlook on Fertility Preservation for Patients With Cancer Is Improving

Advanced Nonsquamous NSCLC FDA Grants Accelerated Approval to Zongertinib